Cyclophosphamide vs placebo
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
- Cyclophosphamide for connective tissue disease–associated interstitial lung disease 2018 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 182 participantsLow